

ASX Announcement

Receipt of notice under section 249N

Sydney Australia, 29 September 2026: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**) (**Recce** or the **Company**) advises, in accordance with ASX Listing Rule 3.17A, that on 25 September 2026 it received a notice stated to be given under section 249N of the *Corporations Act 2001* (Cth) (**Corporations Act**) from Mr Gavin William Brown, a substantial holder of the Company holding more than 5% of the Company's issued shares. The notice was accompanied by a members' statement under section 249P of the Corporations Act.

Proposed resolutions

The notice proposes two resolutions:

- **Resolution A (special resolution):** to amend the Company's constitution to insert a new clause to allow members in general meeting, by ordinary resolution, to express an opinion or make a request or recommendation to the directors about the exercise of powers vested in the directors. Any such resolution would be advisory only and would not be binding, but would require directors to announce their response within 30 days.
- **Resolution B (ordinary resolution, conditional on Resolution A being passed):** requesting that the directors establish a special advisory council, independent of the Company's current directors and executives, to conduct an independent review within 60 days. The review would cover clinical programs, commercialisation strategy, capital structure and funding, board and executive structure and remuneration and consulting arrangements. The resolution requests that the report be published on ASX and that the directors announce which recommendations they will implement.

Recce is assessing the validity of the proposed resolutions.

Timing of the proposed resolutions

If the proposed resolutions are valid they will be included in the notice of the Company's next general meeting at which they are eligible to be considered, together with the response and voting recommendations of the board.

Nomination of directors

The Company also received nominations of Dr Paul MacLeman, Dr Jurgen Michaelis, Mr Amos Meltzer and Ms Diana Forsyth for election as directors at the AGM, together with each candidate's



ASX: RCE, FSE: R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 T +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

consent to act, from Mr Brown. The Company is reviewing the nominations against the requirements of its constitution and the ASX Listing Rules. Resolutions for the election of each validly nominated candidate will be included in the notice of the Company's Annual General Meeting, together with the board's recommendations.

No action required

Shareholders do not need to take any action at this time. The Company will keep the market informed in accordance with its continuous disclosure obligations.

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Incentives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.